Pricing Log in Create free account
Saturday 17 October 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%
Market cap
$10.7B
P/E
32.9×
Fwd P/E
24.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Dr. Reddy's Laboratories Ltd (RDY) Business Profile

Updated before January 2025

Company Overview

Dr. Reddy’s Laboratories Ltd (RDY) is a globally recognized pharmaceutical company headquartered in Hyderabad, India. Established in 1984 by Dr. Kallam Anji Reddy, the company has grown into a multinational organization with a presence in over 25 countries. Dr. Reddy’s Laboratories is listed on the New York Stock Exchange (NYSE) and the National Stock Exchange of India (NSE). The company is led by a strong leadership team, with G.V. Prasad serving as Co-Chairman and Managing Director, and Erez Israeli as the Chief Executive Officer. Over the years, Dr. Reddy’s has built a reputation for innovation, quality, and affordability in the pharmaceutical industry.

Core Business Segments

Dr. Reddy’s Laboratories operates across several core business segments, offering a diverse range of products and services:

1. Generic Medicines

Dr. Reddy’s is a leading player in the generics market, offering affordable alternatives to branded drugs. The company provides a wide range of generic formulations across therapeutic areas such as oncology, cardiovascular, gastrointestinal, and dermatology. Key products include:

  • Omeprazole (for acid reflux)
  • Atorvastatin (for cholesterol management)
  • Azacitidine (for cancer treatment)

2. Active Pharmaceutical Ingredients (APIs)

Dr. Reddy’s is a significant supplier of APIs, which are the active components used in drug manufacturing. The company produces APIs for both its own formulations and external clients. Key API products include:

  • Ibuprofen
  • Naproxen
  • Ciprofloxacin

3. Proprietary Products

This segment focuses on innovative and differentiated products, including specialty drugs and biosimilars. Dr. Reddy’s has developed biosimilars for complex diseases such as cancer and autoimmune disorders. Notable products include:

  • Rituximab (biosimilar for cancer treatment)
  • Pegfilgrastim (biosimilar for neutropenia)

4. Over-the-Counter (OTC) Products

Dr. Reddy’s offers a range of OTC products, including pain relievers, cold and flu medications, and nutritional supplements. Popular OTC brands include:

  • Nise Gel (pain relief)
  • Celevida (nutritional supplement for diabetes management)

5. Pharmaceutical Services and Active Ingredients (PSAI)

This segment provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. Dr. Reddy’s supports clients in drug development, clinical trials, and large-scale manufacturing.

Business Model

Dr. Reddy’s Laboratories operates on a vertically integrated business model, which allows the company to control the entire value chain—from research and development (R&D) to manufacturing and distribution. The company invests heavily in R&D to develop new formulations, biosimilars, and proprietary products. Revenue is generated through the sale of generic medicines, APIs, proprietary products, and contract manufacturing services. Dr. Reddy’s also leverages strategic partnerships and acquisitions to expand its product portfolio and market reach.

Strategic Direction

Dr. Reddy’s Laboratories has outlined a clear strategic direction to drive future growth:

  • Expansion in Biosimilars: The company aims to strengthen its position in the biosimilars market by developing new products for oncology and autoimmune diseases.
  • Digital Transformation: Dr. Reddy’s is investing in digital technologies to enhance operational efficiency and improve customer experiences.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting green manufacturing practices and increasing the use of renewable energy.
  • Geographic Expansion: Dr. Reddy’s plans to expand its presence in emerging markets such as China, Brazil, and Russia, while maintaining a strong foothold in developed markets like the US and Europe.
  • Focus on Innovation: The company continues to invest in R&D to develop innovative therapies and address unmet medical needs.

Competitive Landscape

Dr. Reddy’s Laboratories operates in a highly competitive pharmaceutical industry. Key competitors include:

  • Sun Pharmaceutical Industries: A leading Indian pharmaceutical company with a strong presence in generics and specialty drugs.
  • Cipla: Known for its focus on respiratory, oncology, and HIV/AIDS therapies.
  • Teva Pharmaceuticals: A global leader in generic medicines and specialty pharmaceuticals.
  • Mylan (now part of Viatris): A major player in generics, biosimilars, and OTC products.
  • Lupin: Specializes in generics, biosimilars, and APIs.

Risk Factors

Dr. Reddy’s Laboratories faces several risks that could impact its business:

  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and non-compliance with quality standards can lead to product recalls and financial penalties.
  • Market Dependence: A significant portion of revenue comes from the US market, making the company vulnerable to changes in pricing regulations and competition.
  • Supply Chain Disruptions: Dependence on raw material imports, particularly from China, exposes the company to supply chain risks.
  • Patent Litigation: Generic drug manufacturers often face legal challenges related to patent infringement.
  • Currency Fluctuations: As a global company, Dr. Reddy’s is exposed to currency exchange risks.

Recent Developments

Dr. Reddy’s Laboratories has made significant strides in recent years:

  • Launch of New Biosimilars: The company introduced several biosimilars in key markets, including Rituximab and Pegfilgrastim.
  • Acquisition of Nimbus Health: Dr. Reddy’s acquired Nimbus Health, a German medical cannabis company, to enter the medical cannabis market.
  • COVID-19 Initiatives: The company played a crucial role in the global fight against COVID-19 by manufacturing and distributing vaccines and antiviral drugs.
  • Digital Initiatives: Dr. Reddy’s launched a digital health platform to provide teleconsultation and e-pharmacy services.

Investment Considerations

Strengths:

  • Strong R&D capabilities and a robust product pipeline.
  • Diversified revenue streams across generics, APIs, and proprietary products.
  • Global presence with a strong foothold in both developed and emerging markets.
  • Commitment to sustainability and innovation.

Risks:

  • Regulatory and compliance challenges.
  • Dependence on the US market for a significant portion of revenue.
  • Exposure to supply chain disruptions and currency fluctuations.

Conclusion

Dr. Reddy’s Laboratories Ltd is a leading pharmaceutical company with a strong global presence and a diversified product portfolio. The company’s focus on innovation, sustainability, and geographic expansion positions it well for future growth. While there are risks associated with regulatory challenges and market dependence, Dr. Reddy’s commitment to quality and affordability makes it a compelling choice for investors and healthcare providers alike.